Base4 Biotechnology
Base4 Biotechnology discovers and develops RNA-targeted small-molecule therapeutics to treat diseases previously considered undruggable. The company combines atomic-scale biochemistry, quantum physics–informed chemistry, and AI-driven structure-based discovery to design and optimize RNA-binding molecules. Its platform integrates computational chemistry, structural biology, and machine learning to advance candidates from discovery through preclinical development. Base4 focuses programs across neurology, oncology, and rare diseases and collaborates with biopharma partners to translate leads toward clinical development.
Base4 Biotechnology
Base4 Biotechnology discovers and develops RNA-targeted small-molecule therapeutics to treat diseases previously considered undruggable. The company combines atomic-scale biochemistry, quantum physics–informed chemistry, and AI-driven structure-based discovery to design and optimize RNA-binding molecules. Its platform integrates computational chemistry, structural biology, and machine learning to advance candidates from discovery through preclinical development. Base4 focuses programs across neurology, oncology, and rare diseases and collaborates with biopharma partners to translate leads toward clinical development.